Study compares heparin to warfarin for treatment of blood clots in patients with cancer

Among patients with active cancer and acute symptomatic venous thromboembolism (VTE; blood clots in the deep veins), the use of the low molecular-weight heparin tinzaparin daily for 6 months compared with warfarin did not significantly reduce recurrent VTE and was not associated with reductions in overall death or major bleeding, but was associated with a lower rate of clinically relevant nonmajor bleeding, according to a study.

from Today's Healthcare News -- ScienceDaily http://ift.tt/1Jfu5yP